CIRCULATING TUMOUR DNA AS A NONINVASIVE BIOMARKER IN MELANOMA
Grant number: 1107126 | Funding period: 2016 - 2020
The expanding repertoire of treatment options in melanoma is bringing into focus the need for improved ways to accurately monitor treatment responses and guide treatment decisions. Many cancers shed small amounts of DNA (ctDNA) into the bloodstream and changes in ctDNA levels have potential to be used as specific markers of response to cancer therapy. This project will evaluate if ctDNA can be used as a form of ‘liquid biopsy’ to guide treatment decisions in patients with melanoma.
Related publications (6)
Detection of cell-free microbial DNA using a contaminant-controlled analysis framework
Enrique Zozaya-Valdes, Stephen Q Wong, Jeanette Raleigh, Athena Hatzimihalis, Sarah Ftouni, Anthony T Papenfuss, Shahneen Sandhu, Mark A Dawson, Sarah-Jane Dawson
BACKGROUND: The human microbiome plays an important role in cancer. Accumulating evidence indicates that commensal microbiome-deri..
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela, Jenny Lee, Leslie Calapre, Stephen Q Wong, Michelle R Pereira, Ashleigh C McEvoy, Anna L Reid, Cleo Robinson, Lydia Warburton, Afaf Abed, Muhammad A Khattak, Tarek M Meniawy, Sarah-Jane Dawson, Shahneen Sandhu, Matteo S Carlino, Alexander M Menzies, Richard A Scolyer, Georgina Long, Benhur Amanuel, Michael Millward
PURPOSE: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic outcomes in patients with metastatic melano..
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Jenny H Lee, Alexander M Menzies, Matteo S Carlino, Ashleigh C McEvoy, Shahneen Sandhu, Alison M Weppler, Russell J Diefenbach, Sarah-Jane Dawson, Richard F Kefford, Michael J Millward, Zeyad Al-Ogaili, Thien Tra, Elin S Gray, Stephen Q Wong, Richard A Scolyer, Georgina Long, Helen Rizos
PURPOSE: Brain involvement occurs in the majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ct..
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, P Middlehurst, A Wallace, J Raleigh, A Hatzimihalis, MA Henderson, M Shackleton, A Haydon, V Mar, DE Gyorki, D Oudit, MA Dawson, RJ Hicks, P Lorigan
BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify pa..
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes
Paul Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter, Devbarna Sinha, Stephen Q Wong, Rishu Agarwal, Ravikiran Vedururu, Kenneth Doig, Chun Yew Fong, Piers Blombery, David Westerman, Mark A Dawson, Sarah-Jane Dawson
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated..
Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma
Stephen Q Wong, Jeanette M Raleigh, Jason Callahan, Ismael A Vergara, Sarah Ftouni, Athena Hatzimihalis, Andrew J Colebatch, Jason Li, Timothy Semple, Kenneth Doig, Christopher Mintoff, Devbarna Sinha, Paul Yeh, Maria Joao Silva, Kathryn Alsop, Heather Thorne, David D Bowtell, David E Gyorki, Gisela Mir Arnau, Carleen Cullinane
Purpose Circulating tumorDNA(ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, ..